licogliflozin

Licogliflozin is an orally bioavailable small molecule that acts as a dual inhibitor of sodium-glucose cotransporter 1 (SGLT1) and sodium-glucose cotransporter 2 (SGLT2). By blocking these transporters in the kidney and gut, it suppresses glucose reabsorption in the proximal renal tubules, leading to increased urinary glucose excretion and reduced blood glucose levels. This mechanism also results in weight loss and favorable metabolic changes. Licogliflozin was developed by Novartis for potential use in obesity, type 2 diabetes mellitus, non-alcoholic steatohepatitis (NASH), hepatic fibrosis, heart failure, and polycystic ovary syndrome. Clinical development has reached phase II for some indications but has been discontinued or terminated for others[1][2][3][4][5][8].

Other names

licogliflozinaLicogliflozin [INN]